Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers

Next Previous
Search
Trial Profile

A First Time in Human, Single Blind, Randomized, Placebo-controlled,Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linerixibat (Primary)
  • Indications Cholestasis; Primary biliary cirrhosis; Pruritus; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors GSK

Most Recent Events

  • 26 Jun 2022 Results from three Phase 1 studies 114985,116511, 205808 and from patients with PBC in two Phase 2 stud, 201000 and other study, presented at The International Liver Congress 2022
  • 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
  • 13 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top